DiaMedica Therapeutics, Inc. (DMAC)
8.45
-0.18
(-2.09%)
USD |
NASDAQ |
Oct 23, 11:03
DiaMedica Therapeutics Net Income (Quarterly) : -10.14M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -10.14M |
| March 31, 2026 | -10.04M |
| December 31, 2025 | -8.74M |
| September 30, 2025 | -8.62M |
| June 30, 2025 | -7.699M |
| March 31, 2025 | -7.707M |
| December 31, 2024 | -7.90M |
| September 30, 2024 | -6.274M |
| June 30, 2024 | -5.119M |
| March 31, 2024 | -5.151M |
| December 31, 2023 | -5.161M |
| September 30, 2023 | -4.471M |
| June 30, 2023 | -4.477M |
| March 31, 2023 | -5.272M |
| December 31, 2022 | -3.751M |
| September 30, 2022 | -3.059M |
| June 30, 2022 | -3.358M |
| March 31, 2022 | -3.508M |
| December 31, 2021 | -3.246M |
| September 30, 2021 | -3.45M |
| June 30, 2021 | -3.274M |
| March 31, 2021 | -3.622M |
| December 31, 2020 | -4.20M |
| September 30, 2020 | -3.193M |
| June 30, 2020 | -2.474M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.425M |
| December 31, 2019 | -2.48M |
| September 30, 2019 | -2.448M |
| June 30, 2019 | -2.469M |
| March 31, 2019 | -3.252M |
| December 31, 2018 | |
| September 30, 2018 | -1.387M |
| June 30, 2018 | -1.735M |
| March 31, 2018 | -0.65M |
| December 31, 2017 | -0.899M |
| September 30, 2017 | -0.8961M |
| June 30, 2017 | -1.071M |
| March 31, 2017 | -1.309M |
| December 31, 2016 | |
| September 30, 2016 | -0.9495M |
| June 30, 2016 | -0.5303M |
| March 31, 2016 | -0.3319M |
| December 31, 2015 | -0.53M |
| September 30, 2015 | -0.2411M |
| June 30, 2015 | -0.3387M |
| March 31, 2015 | -0.453M |
| December 31, 2014 | -0.9278M |
| September 30, 2014 | -0.9041M |
| June 30, 2014 | -1.199M |
| March 31, 2014 | -2.037M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 10.14M |
| EPS Diluted (Quarterly) | -0.1881 |
| Enterprise Value | 422.06M |
| Earnings Yield | -8.45% |
| Normalized Earnings Yield | -8.450 |